Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison
ABSTRACT The aim of this work was to evaluate patients with chronic migraine treated with botulinum toxin A (BT-A) and compare this with low level laser therapy (LLLT), referencing: pain days, pain intensity, intake of drugs/self-medication, anxiety and sleep disorders. Methods: Patients were random...
Gespeichert in:
| Veröffentlicht in: | Arquivos de neuro-psiquiatria 2018-10, Vol.76 (10), p.663-667 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 667 |
|---|---|
| container_issue | 10 |
| container_start_page | 663 |
| container_title | Arquivos de neuro-psiquiatria |
| container_volume | 76 |
| creator | Loeb, Luana Mazzacoratti Amorim, Rebeca Padrão Mazzacoratti, Maria da Graça Naffah Scorza, Fulvio Alexandre Peres, Mario Fernando Prieto |
| description | ABSTRACT
The aim of this work was to evaluate patients with chronic migraine treated with botulinum toxin A (BT-A) and compare this with low level laser therapy (LLLT), referencing: pain days, pain intensity, intake of drugs/self-medication, anxiety and sleep disorders.
Methods:
Patients were randomized into two groups: BT-A group (n = 18) and LLLT group (n = 18). Each patient kept three pain diaries: one before (baseline) (30 days), one during treatment (30 days) and one after the post-treatment phase (30 days). Repeated ANOVA plus the Bonferroni post-test, Student's t test, and factorial analysis were applied, and p < 0.05 was accepted as significant.
Results:
Our data showed that both treatments were able to reduce headache days, acute medication intake and decrease the intensity of pain. Anxiety was reduced in the BT-A group, while sleep disturbance was reduced in the LLLT group.
Conclusion:
Our data showed that both treatments can be used to treat chronic migraine, without notable differences between them. |
| doi_str_mv | 10.1590/0004-282X20180109 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_scielo_journals_S0004_282X2018001000663</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><scielo_id>S0004_282X2018001000663</scielo_id><doaj_id>oai_doaj_org_article_f41e6ed73b4548b6b87ed21c82f9340f</doaj_id><sourcerecordid>2161057626</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-841a2819de707a8fafe8557036195c4650f6d20f08f9ca2e4d3c03c754e0e3243</originalsourceid><addsrcrecordid>eNpdkktv1DAUhSMEoqXwA9ggS2ymi5Trt8NuWvGoNBILBomd5XFuOh4l8WAnffx7UqYTpK4s2ed8vj4-RfGewgWVFXwCAFEyw34zoAYoVC-KU6q0KQVj-mVxOp-fFG9y3gEwUVX6dXHCQTAtQZ4Wu8s4jG3ox44M8T70ZEkWl-tyeU5uMeUxkzbelS3eYktalzGRYYvJ7R_IYrVarc_J5PDbFPvgSRdukgs9kiGhGzrsh8_EER-7vUshx_5t8apxbcZ3T-tZ8evrl_XV93L149v11XJVeknNUBpBHTO0qlGDdqZxDRopNXBFK-mFktComkEDpqm8Yyhq7oF7LQUCcib4WXF94NbR7ew-hc6lBxtdsP82YrqxLg3Bt2gbQVFhrflGSGE2amM01ox6w5qKC2gm1sWBlX3ANtpdHFM_DW9_PmZr5-yn8AGU4pNhcTDsU_wzYh5sF7LHtnU9xjFbRjkXXCteTdKPz6QznVFFQWrF1KSiB5VPMeeEzfwiCvaxBfY4yf2xBZPnwxN53HRYz47jt08COAiGbcAO_1_8nDk3i_8Fa0S1qA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2161057626</pqid></control><display><type>article</type><title>Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison</title><source>DOAJ Directory of Open Access Journals</source><source>Thieme Connect Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Loeb, Luana Mazzacoratti ; Amorim, Rebeca Padrão ; Mazzacoratti, Maria da Graça Naffah ; Scorza, Fulvio Alexandre ; Peres, Mario Fernando Prieto</creator><creatorcontrib>Loeb, Luana Mazzacoratti ; Amorim, Rebeca Padrão ; Mazzacoratti, Maria da Graça Naffah ; Scorza, Fulvio Alexandre ; Peres, Mario Fernando Prieto</creatorcontrib><description>ABSTRACT
The aim of this work was to evaluate patients with chronic migraine treated with botulinum toxin A (BT-A) and compare this with low level laser therapy (LLLT), referencing: pain days, pain intensity, intake of drugs/self-medication, anxiety and sleep disorders.
Methods:
Patients were randomized into two groups: BT-A group (n = 18) and LLLT group (n = 18). Each patient kept three pain diaries: one before (baseline) (30 days), one during treatment (30 days) and one after the post-treatment phase (30 days). Repeated ANOVA plus the Bonferroni post-test, Student's t test, and factorial analysis were applied, and p < 0.05 was accepted as significant.
Results:
Our data showed that both treatments were able to reduce headache days, acute medication intake and decrease the intensity of pain. Anxiety was reduced in the BT-A group, while sleep disturbance was reduced in the LLLT group.
Conclusion:
Our data showed that both treatments can be used to treat chronic migraine, without notable differences between them.</description><identifier>ISSN: 0004-282X</identifier><identifier>ISSN: 1678-4227</identifier><identifier>EISSN: 1678-4227</identifier><identifier>DOI: 10.1590/0004-282X20180109</identifier><identifier>PMID: 30427505</identifier><language>eng</language><publisher>Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil: Thieme Revinter Publicações Ltda</publisher><subject>Anxiety ; Botulinum toxin ; Botulinum toxin type A ; botulism ; Headache ; Lasers ; low level laser therapy ; Migraine ; Migraine disorders ; NEUROSCIENCES ; Pain ; Patients ; PSYCHIATRY ; Sleep ; Sleep disorders</subject><ispartof>Arquivos de neuro-psiquiatria, 2018-10, Vol.76 (10), p.663-667</ispartof><rights>Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon.</rights><rights>Copyright Arquivos de Neuro-Psiquiatria Oct 2018</rights><rights>This work is licensed under a Creative Commons Attribution 4.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-841a2819de707a8fafe8557036195c4650f6d20f08f9ca2e4d3c03c754e0e3243</citedby><cites>FETCH-LOGICAL-c518t-841a2819de707a8fafe8557036195c4650f6d20f08f9ca2e4d3c03c754e0e3243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.thieme-connect.de/products/ejournals/pdf/10.1590/0004-282X20180109.pdf$$EPDF$$P50$$Gthieme$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.thieme-connect.de/products/ejournals/html/10.1590/0004-282X20180109$$EHTML$$P50$$Gthieme$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,864,885,20890,27923,27924,54586,54614</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30427505$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Loeb, Luana Mazzacoratti</creatorcontrib><creatorcontrib>Amorim, Rebeca Padrão</creatorcontrib><creatorcontrib>Mazzacoratti, Maria da Graça Naffah</creatorcontrib><creatorcontrib>Scorza, Fulvio Alexandre</creatorcontrib><creatorcontrib>Peres, Mario Fernando Prieto</creatorcontrib><title>Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison</title><title>Arquivos de neuro-psiquiatria</title><addtitle>Arq Neuropsiquiatr</addtitle><description>ABSTRACT
The aim of this work was to evaluate patients with chronic migraine treated with botulinum toxin A (BT-A) and compare this with low level laser therapy (LLLT), referencing: pain days, pain intensity, intake of drugs/self-medication, anxiety and sleep disorders.
Methods:
Patients were randomized into two groups: BT-A group (n = 18) and LLLT group (n = 18). Each patient kept three pain diaries: one before (baseline) (30 days), one during treatment (30 days) and one after the post-treatment phase (30 days). Repeated ANOVA plus the Bonferroni post-test, Student's t test, and factorial analysis were applied, and p < 0.05 was accepted as significant.
Results:
Our data showed that both treatments were able to reduce headache days, acute medication intake and decrease the intensity of pain. Anxiety was reduced in the BT-A group, while sleep disturbance was reduced in the LLLT group.
Conclusion:
Our data showed that both treatments can be used to treat chronic migraine, without notable differences between them.</description><subject>Anxiety</subject><subject>Botulinum toxin</subject><subject>Botulinum toxin type A</subject><subject>botulism</subject><subject>Headache</subject><subject>Lasers</subject><subject>low level laser therapy</subject><subject>Migraine</subject><subject>Migraine disorders</subject><subject>NEUROSCIENCES</subject><subject>Pain</subject><subject>Patients</subject><subject>PSYCHIATRY</subject><subject>Sleep</subject><subject>Sleep disorders</subject><issn>0004-282X</issn><issn>1678-4227</issn><issn>1678-4227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>0U6</sourceid><sourceid>DOA</sourceid><recordid>eNpdkktv1DAUhSMEoqXwA9ggS2ymi5Trt8NuWvGoNBILBomd5XFuOh4l8WAnffx7UqYTpK4s2ed8vj4-RfGewgWVFXwCAFEyw34zoAYoVC-KU6q0KQVj-mVxOp-fFG9y3gEwUVX6dXHCQTAtQZ4Wu8s4jG3ox44M8T70ZEkWl-tyeU5uMeUxkzbelS3eYktalzGRYYvJ7R_IYrVarc_J5PDbFPvgSRdukgs9kiGhGzrsh8_EER-7vUshx_5t8apxbcZ3T-tZ8evrl_XV93L149v11XJVeknNUBpBHTO0qlGDdqZxDRopNXBFK-mFktComkEDpqm8Yyhq7oF7LQUCcib4WXF94NbR7ew-hc6lBxtdsP82YrqxLg3Bt2gbQVFhrflGSGE2amM01ox6w5qKC2gm1sWBlX3ANtpdHFM_DW9_PmZr5-yn8AGU4pNhcTDsU_wzYh5sF7LHtnU9xjFbRjkXXCteTdKPz6QznVFFQWrF1KSiB5VPMeeEzfwiCvaxBfY4yf2xBZPnwxN53HRYz47jt08COAiGbcAO_1_8nDk3i_8Fa0S1qA</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Loeb, Luana Mazzacoratti</creator><creator>Amorim, Rebeca Padrão</creator><creator>Mazzacoratti, Maria da Graça Naffah</creator><creator>Scorza, Fulvio Alexandre</creator><creator>Peres, Mario Fernando Prieto</creator><general>Thieme Revinter Publicações Ltda</general><general>Arquivos de Neuro-Psiquiatria</general><general>Academia Brasileira de Neurologia - ABNEURO</general><general>Academia Brasileira de Neurologia (ABNEURO)</general><scope>0U6</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>GPN</scope><scope>DOA</scope></search><sort><creationdate>201810</creationdate><title>Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison</title><author>Loeb, Luana Mazzacoratti ; Amorim, Rebeca Padrão ; Mazzacoratti, Maria da Graça Naffah ; Scorza, Fulvio Alexandre ; Peres, Mario Fernando Prieto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-841a2819de707a8fafe8557036195c4650f6d20f08f9ca2e4d3c03c754e0e3243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anxiety</topic><topic>Botulinum toxin</topic><topic>Botulinum toxin type A</topic><topic>botulism</topic><topic>Headache</topic><topic>Lasers</topic><topic>low level laser therapy</topic><topic>Migraine</topic><topic>Migraine disorders</topic><topic>NEUROSCIENCES</topic><topic>Pain</topic><topic>Patients</topic><topic>PSYCHIATRY</topic><topic>Sleep</topic><topic>Sleep disorders</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Loeb, Luana Mazzacoratti</creatorcontrib><creatorcontrib>Amorim, Rebeca Padrão</creatorcontrib><creatorcontrib>Mazzacoratti, Maria da Graça Naffah</creatorcontrib><creatorcontrib>Scorza, Fulvio Alexandre</creatorcontrib><creatorcontrib>Peres, Mario Fernando Prieto</creatorcontrib><collection>Thieme Connect Journals Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SciELO</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Arquivos de neuro-psiquiatria</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Loeb, Luana Mazzacoratti</au><au>Amorim, Rebeca Padrão</au><au>Mazzacoratti, Maria da Graça Naffah</au><au>Scorza, Fulvio Alexandre</au><au>Peres, Mario Fernando Prieto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison</atitle><jtitle>Arquivos de neuro-psiquiatria</jtitle><addtitle>Arq Neuropsiquiatr</addtitle><date>2018-10</date><risdate>2018</risdate><volume>76</volume><issue>10</issue><spage>663</spage><epage>667</epage><pages>663-667</pages><issn>0004-282X</issn><issn>1678-4227</issn><eissn>1678-4227</eissn><abstract>ABSTRACT
The aim of this work was to evaluate patients with chronic migraine treated with botulinum toxin A (BT-A) and compare this with low level laser therapy (LLLT), referencing: pain days, pain intensity, intake of drugs/self-medication, anxiety and sleep disorders.
Methods:
Patients were randomized into two groups: BT-A group (n = 18) and LLLT group (n = 18). Each patient kept three pain diaries: one before (baseline) (30 days), one during treatment (30 days) and one after the post-treatment phase (30 days). Repeated ANOVA plus the Bonferroni post-test, Student's t test, and factorial analysis were applied, and p < 0.05 was accepted as significant.
Results:
Our data showed that both treatments were able to reduce headache days, acute medication intake and decrease the intensity of pain. Anxiety was reduced in the BT-A group, while sleep disturbance was reduced in the LLLT group.
Conclusion:
Our data showed that both treatments can be used to treat chronic migraine, without notable differences between them.</abstract><cop>Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil</cop><pub>Thieme Revinter Publicações Ltda</pub><pmid>30427505</pmid><doi>10.1590/0004-282X20180109</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0004-282X |
| ispartof | Arquivos de neuro-psiquiatria, 2018-10, Vol.76 (10), p.663-667 |
| issn | 0004-282X 1678-4227 1678-4227 |
| language | eng |
| recordid | cdi_scielo_journals_S0004_282X2018001000663 |
| source | DOAJ Directory of Open Access Journals; Thieme Connect Journals Open Access; EZB-FREE-00999 freely available EZB journals |
| subjects | Anxiety Botulinum toxin Botulinum toxin type A botulism Headache Lasers low level laser therapy Migraine Migraine disorders NEUROSCIENCES Pain Patients PSYCHIATRY Sleep Sleep disorders |
| title | Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T22%3A16%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Botulinum%20toxin%20A%20(BT-A)%20versus%20low-level%20laser%20therapy%20(LLLT)%20in%20chronic%20migraine%20treatment:%20a%20comparison&rft.jtitle=Arquivos%20de%20neuro-psiquiatria&rft.au=Loeb,%20Luana%20Mazzacoratti&rft.date=2018-10&rft.volume=76&rft.issue=10&rft.spage=663&rft.epage=667&rft.pages=663-667&rft.issn=0004-282X&rft.eissn=1678-4227&rft_id=info:doi/10.1590/0004-282X20180109&rft_dat=%3Cproquest_doaj_%3E2161057626%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2161057626&rft_id=info:pmid/30427505&rft_scielo_id=S0004_282X2018001000663&rft_doaj_id=oai_doaj_org_article_f41e6ed73b4548b6b87ed21c82f9340f&rfr_iscdi=true |